Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 51 to 60 of 86

TitleReference numberPublishedLast updated
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Lung cancer in adultsQS17
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancerMIB137

Results per page

  1. 10
  2. 25
  3. 50
  4. All